Skip to main content

Table 3 Literature review on invasive micropapillary carcinoma of the breast

From: Prognosis of lymphotropic invasive micropapillary breast carcinoma analyzed by using data from the National Cancer Database

Study

Cases

Age (years)a

ER+ (%)

PR+ (%)

HER2+ (%)

RLN+ (%)

DSS (%)

OS (%)

Follow-up durationa

NCDB (current study)

1818

60

84.3

73.9

19.4

55.2

87.5 at 5 years

4 years

Kim et al. [2]

38

47.3

19.4

19.4

78.9

Chen et al. [3]

624

61.7

84.8

69.9

52.9

92 at 5 years

84 at 5 years

33.0 months

Yu et al. [5]

267

47

66.3

66.3

28.8

62.9

97.7 at 5 years

59 months

Chen et al. [6]

95

58.9

83.2

74.7

21.1

72.6

81.9 at 5 years

60 months

Shi et al. [7]

188

52.7

85.1

78.2

29.9

73.4

75.9 at 5 years

40.5 months

Cui et al. [8]

25

52.3

88

64

80

36.5 months

Walsh & Bleiweiss [37]

80

58.8

90.6

70.3

59.1

72.3

Vingiani et al. [38]

49

52.7

87.8

69.4

18.4

69.4

89.8 at 6 years

6 years

Adrada et al. [39]

29

56a

82

61

43

62

Chen et al. [40]

100

50

46

27

84.8

63.3

59 at 5 years

60.1 months

De La Cruz et al. [41]

16

50.9

50

31.2

50

92.9

75

38 months

Luna-Moré et al. [42]

68

54.3

74.5

46.3

90.5

63

52.6 months

Middleton et al. [43]

14

50

25

12.5

70 at 5 years

57.6 months

Nassar et al. [44]

83

61

71

77

40

46

7 years

Paterakos et al. [45]

18

55

61.1

< 50

95.2

50 at 44 months

165.6 months

Pettinato et al. [46]

62

57

32

20

95

90

49

5.2 years

Yamaguchi et al. [47]

15

60.1

73

67

33.3

46.6

Zekioglu et al. [48]

53

52.5

68

61

68.8

72

56.5 months

  1. ER estrogen receptor, + positivity, PR progesterone receptor, HER2 human epidermal growth factor receptor 2, RLN regional lymph node metastasis, DSS disease-specific survival, OS overall survival, NCDB National Cancer Database, – not available or not reported
  2. aMedian or mean age